Efficacy of @entity1037 in the treatment of @entity716 in dementia with XXXX .

@entity1 @entity137 @entity304 @entity1833 @entity1832 @entity716 @entity195 @entity21 @entity1037
OBJECTIVE: This study sought to determine whether @entity1 with @entity1832 ( @entity1832 ) and @entity716 responded to treatment with @entity1037 . METHODS: This was a post hoc analysis of a subgroup of @entity1 with @entity1832 included in a larger double-blind, placebo-controlled, randomized parallel group trial of @entity1037 for the treatment of @entity716 in @entity1 with @entity195 . @entity1 meeting the consensus criteria for @entity1832 and exhibiting @entity304 and @entity1833 were selected from the initial study. @entity716 was assessed with the Neuropsychiatric Inventory/Nursing Home (NPI-NH) version and the Brief Psychiatric Rating Scale (BPRS). @entity21 were evaluated with the Simpson-Angus scale. RESULTS: Twenty-nine @entity1 met the criteria for @entity1832 ; 10 were randomized to placebo, 5 received 5 mg of @entity1037 , 7 received 10 mg of @entity1037 and 7 received 15 mg of @entity1037 . @entity1 with @entity1832 treated with 5 mg of @entity1037 showed significant reductions in delusions and @entity1833 . @entity1 treated with 10 mg showed a significant reduction in the NPI-NH delusion subscale score. No significant differences were found between the 15-mg group and the placebo group. Confirmatory findings emerged from an analysis of the BPRS. Caregivers reported decreased disruptions in their occupational routines for the group receiving 5 or 10 mg of @entity1037 . There was no significant exacerbation of @entity304 in any study group, no decrement in Mini-Mental State Examination scores in any of the treatment groups, and symptoms suggestive of anticholinergic @entity137 did not differ among treatment groups. CONCLUSIONS: This preliminary analysis suggests that @entity1037 (5 or 10 mg) reduces @entity716 in @entity1 with @entity1832 without worsening @entity304 .
